轻症急性胆源性胰腺炎手术时机的临床研究

The timing of laparoscopic cholecystectomy for mild acute biliary pancreatitis

目的探讨轻症急性胆源性胰腺炎行腹腔镜胆囊切除术的手术时机。方法回顾性收集2021年7月-2023年6月宿州市立医院肝胆外科收治的48例轻症急性胆源性胰腺炎患者的临床资料,按照发病后手术时间将其分为两组,早期手术组(25例,发病后7天内行LC术)和晚期手术组(23例,发病7天后于出院前行LC术),比较两组平均住院天数、平均住院费用、手术时间、术中出血量、中转开腹率、术后并发症。结果48例患者均成功完成LC术。早期组平均住院时间为12.44±1.65天,平均住院费用1.82±0.25万元,晚期组平均住院时间为20.53天,平均住院费用2.64±0.45万元。早期手术组平均住院时间及平均住院费用均少于晚期手术组(P<0.05),而两组的手术时间、术中出血量、中转开腹率及术后并发症对比均无统计学意义(P>0.05)。结论对于轻症急性胆源性胰腺炎早期行LC术安全可行,同时明显降低住院时间和住院费用,值得临床推广。

Objective To explore the timing of laparoscopic cholecystectomy for mild acute biliary pancreatitis.Methods The clinical data of 48 patients with mild acute biliary pancreatitis admitted to the Department of Hepatobiliary Surgery of Suzhou Mu-nicipal Hospital from July 2021 to June 2023 were retrospectively analyzed.They were divided into two groups:the early operation group(25 patients,LC was performed within 7 days after the onset)and the late operation group(23 patients,LC was performed 7 days after onset,before discharge),Observe the average hospitalization days,average hospitalization expenses,operation time,intraop-erative bleeding,conversion to laparotomy rate and postoperative complications of the two groups.Results All 48 patients successfully underwent laparoscopic cholecystectomy.The average length of stay in the early group was 12.44±1.65 days,the average cost was 18200±2500 yuan,the average length of stay in the late group was 20.53±3.75 days,and the average cost was 26400±4500 yuan.The average length of stay and the average cost of stay in the early group were lower than those in the late group(P<0.05),which was statistically significantly.However,there was no statistically significant difference between the two groups in operation time,intr-aoperative bleeding,conversion rate of laparotomy and postoperative complications(P>0.05).Conclusion LC is safe and feasible treatment for early mild acute biliary pancreatitis,and it can significantly reduce the length of stay and hospitalization costs,which is worthy of clinical promotion.